The blockbuster weight loss drug Wegovy is now approved in the U.S. for heart health. But some health plans and employers are still reluctant to cover The drug due to its hefty $1,350 monthly price tag, which they say could significantly strain their budgets. That may not translate to wider insurance coverage of the weekly injection drug from Novo Nordisk and similar obesity treatments just yet.